These seminal studies led to FDA and EMA approval of the following indications for the use of venetoclax in CLL: monotherapy in the presence of 17p deletion or TP53 mutation in patients who are unsuitable for or have failed a BCR inhibitor, or in the absence of 17p deletion or TP53 mutation in patients who have failed both chemoimmunotherapy and a BCR inhibitor; in combination with rituximab in patients who have received at least one prior therapy; in combination with obinutuzumab in previously untreated patients. Here, BCR is linked to B-cell chronic lymphocytic leukemia.